BERLIN (Reuters) – Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Stockholders will also receive a non-tradeable contingent value right (CVR) for $4 per share, representing a total deal value of up to approximately $1.5 billion, said the company.
The transaction is expected to close in the first quarter of 2025.
